Relationship between EGFR mutation and computed tomography characteristics of the lung in patients with lung adenocarcinoma

Abstract

BackgroundThe aim of this study was to investigate the relationship between EGFR mutation and computed tomography (CT) features in patients with adenocarcinoma of the lung.MethodsOne hundred and ninety two lung adenocarcinoma patients who underwent surgery were retrospectively included in this study. Examination of EGFR gene mutation was performed on all resected tumor samples. The 192 recruited lung adenocarcinoma patients were divided into groups according to EGFR mutation status: patients with mutations in exons 18–21 (effective mutated, n = 61) and non‐mutated (n = 131). The clinical characteristics and lung CT imaging features of the two groups were recorded and compared. Univariate and logistic regression analysis were performed to identify the independent risk factors relevant to effective EGFR gene mutation.ResultsThe independent risk factors relevant to effective EGFR mutation were evaluated by logistic regression test. The results indicated that female gender (odds ratio [OR] 3.23), lung CT features of lymphangitis carcinomatosa (OR 2.66), semi‐solid lesion density (OR 3.56), and spicule sign (OR 1.61) were independent risk factors relevant to EGFR mutation.ConclusionFemale patients with lung CT features of lymphangitis carcinomatosa, semi‐solid lesion density, and spicule sign are more prone to harbor EGFR gene mutations and are more likely to benefit from targeted therapy.

The relation between distant metastasis and genetic change type in stage IV lung adenocarcinoma patients at diagnosis

“…This difference may be due to the patient characteristics in our study. EGFR mutation is more common in women and non-smokers, 12 but in our study, male patients were more (76.2% of all patients) and also smoking status could not be learned in 58.6% of all patients. As known, brain metastasis risk is high in patients with ALK fusion change positive, but in our study no correlation was found with ALK and brain metastases.…”

Thoracic Ct-Scan With Egfr Mutations in Pulmonary Adenocarcinoma Patients With Pulmonary Metastases at Dr. Moewardi Hospital, Surakarta, Indonesia

“…This study found that the highest age of patients with pulmonary adenocarcinoma with pulmonary metastases was in subjects aged >58, with 40 (61.6%) subjects. It is estimated that 53% of lung cancer cases occur in individuals aged 55-74 years, and 37% occur in people aged >75 years (Qiu, et al, 2019). The study by Wu, et al (2017) showed that patients with younger age (<50 years) had a lower chance of developing an EGFR mutation in cases of pulmonary adenocarcinoma.…”

A nomogram based on 18F-fluorodeoxyglucose PET/CT and clinical features to predict epidermal growth factor receptor mutation status in patients with lung adenocarcinoma

“…According to these data and our results, Asian ethnicity, female sex, and never smoking are strong predictors of EGFR mutations in patients with LADC. Several studies (9)(10)(11)(12)(13) have reported connections between EGFR gene phenotypes and PET metabolic or volumetric parameters of LADCs, such as the SUV max , SUV mean , MTV, and TLG, among which the SUV max is the most studied. Most of the previous studies reported that these parameters were significantly lower in EGFR-mutated LADCs than in EGFR wild-type LADCs, which is consistent with our results; however, contrasting results still exist.…”

“…18 F-Fluorodeoxyglucose positron emission tomography/ CT ( 18 F-FDG PET/CT) is a hybrid molecular imaging technique that provides simultaneous metabolic and morphological information, and has great benefit for the diagnosis, staging, and prognostication of patients with LADCs (6)(7)(8). The metabolic and morphological characteristics of EGFR-mutated LADCs are distinct from those of EGFR wild-type LADCs (9)(10)(11)(12)(13), but the results of previous studies are inconsistent, such as either higher or lower value of those parameters being more indicative of EGFR mutation. Two meta-analyses revealed a moderate ability of PET metabolic parameters alone (14) and CT features alone (15) to discriminate EGFR-mutated and wild-type LADCs.…”